Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Emergent Biosolutions (EBS)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 1,916,406
  • Shares Outstanding, K 41,400
  • Annual Sales, $ 488,780 K
  • Annual Income, $ 51,780 K
  • 36-Month Beta 1.24
  • Price/Sales 3.90
  • Price/Cash Flow 16.14
  • Price/Book 2.86

Price Performance

See More
Period Period Low Period High Performance
1-Month
37.06 +25.31%
on 11/17/17
47.37 -1.96%
on 12/14/17
+8.08 (+21.06%)
since 11/15/17
3-Month
36.38 +27.65%
on 11/15/17
47.37 -1.96%
on 12/14/17
+8.38 (+22.02%)
since 09/15/17
52-Week
27.94 +66.21%
on 04/06/17
47.37 -1.96%
on 12/14/17
+10.61 (+29.61%)
since 12/15/16

Most Recent Stories

More News
Lilly Issues Guidance for 2018, New Drugs to Drive Top Line

Eli Lilly (LLY) issues financial guidance for 2018 and also reaffirms the previously issued 2017 projection as well as its long-term expectations.

NVO : 52.55 (-0.59%)
EBS : 46.60 (+0.67%)
LLY : 87.24 (+0.86%)
SNY : 43.12 (+0.07%)
Five Marvelous Momentum Stocks to Buy Now

These five Zacks Rank #1 (Strong Buy) stocks are surging on huge demand and breaking higher

SKX : 38.16 (+3.36%)
FSLR : 69.33 (+2.12%)
DAVE : 7.09 (-2.88%)
EBS : 46.60 (+0.67%)
GRPN : 5.22 (-1.69%)
BioMarin Pharmaceutical (BMRN) Jumps: Stock Rises 7.5%

BioMarin Pharmaceutical (BMRN) saw a big move last session, as its shares jumped more than 7% on the day, amid huge volumes.

EBS : 46.60 (+0.67%)
BMRN : 90.52 (+2.25%)
Emergent BioSolutions Awarded Department of National Defence Contract to Supply Anthrasil to the Canadian Government

Emergent BioSolutions Inc. (NYSE:EBS) today announced that it has been awarded a contract by the Department of National Defence (DND) valued at approximately $8 million to deliver Anthrasil (Anthrax Immune...

EBS : 46.60 (+0.67%)
Vertex Kalydeco Study Successful in Children Aged 1-2 Years

Vertex Pharmaceuticals' (VRTX) phase III study evaluating Kalydeco in children as young as one year meets its primary safety endpoint.

XOMA : 31.95 (+1.14%)
MYGN : 33.51 (+1.12%)
EBS : 46.60 (+0.67%)
VRTX : 145.09 (+1.80%)
4 Biotech Stocks to Better Your Financial Health This Winter

The biotech industry shows a solid performance so far this year except for a brief slump in between of late. However, it is a good idea to select stocks from a sector that is fundamentally strong.

SGMO : 16.15 (-1.52%)
XOMA : 31.95 (+1.14%)
SRPT : 53.10 (-1.03%)
EBS : 46.60 (+0.67%)
New Strong Buy Stocks for December 1st

New Strong Buy Stocks for December 1st

MCFT : 22.03 (-0.23%)
OC : 86.98 (+1.38%)
COHU : 22.37 (+2.71%)
EBS : 46.60 (+0.67%)
STO : 20.15 (-1.37%)
Emergent BioSolutions to Host 2017 Analyst & Investor Day

Emergent BioSolutions Inc. (NYSE:EBS) today announced that the company will host an analyst and investor day on December 7, 2017 in New York City.

EBS : 46.60 (+0.67%)
New Strong Buy Stocks for November 28th

New Strong Buy Stocks for November 28th

MEI : 40.10 (+2.43%)
SCMP : 17.00 (+1.49%)
EBS : 46.60 (+0.67%)
PKX : 76.32 (+0.69%)
BAK : 26.77 (-0.11%)
Emergent BioSolutions Receives FDA Approval to Manufacture ACAM2000 at Canton, Massachusetts Facility

Emergent BioSolutions Inc. (NYSE:EBS) today announced that the U.S. Food and Drug Administration (FDA) has approved the supplemental Biologics License Application (sBLA) for the manufacture of ACAM2000,...

EBS : 46.60 (+0.67%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 96% Buy with a Strengthening short term outlook on maintaining the current direction.

Longer term, the trend strength is Maximum. Long term indicators fully support a continuation of the trend.

The market is approaching overbought territory. Be watchful of a trend reversal.

See More

Business Summary

Emergent BioSolutions Inc. is strongly committed to the highest standards of ethical conduct and corporate governance. These standards are consistent with their corporate culture. The company understands that adhering to sound principles of corporate governance is critical to earning and maintaining...

See More

Key Turning Points

2nd Resistance Point 47.81
1st Resistance Point 47.05
Last Price 46.60
1st Support Level 45.85
2nd Support Level 45.41

See More

52-Week High 47.37
Last Price 46.60
Fibonacci 61.8% 39.95
Fibonacci 50% 37.65
Fibonacci 38.2% 35.36
52-Week Low 27.94

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
New Chart Menu
Right-click anywhere on the chart to open the Interactive Chart menu.